Enhanced Expression of ABCB1 and Nrf2 in CD133-Positive Cancer Stem Cells Associates with Doxorubicin Resistance. (12th August 2020)

• Record Type: Journal Article
• Authors: Goto, Shinji; Kawabata, Tsuyoshi; Li, Tao-Sheng
• Other Names: Ballini Andrea Academic Editor.
• Is Part Of: Stem cells international. Volume 2020(2020)
• Publication Date: 2020-08-12
• Subjects: Stem Cells -- Periodicals; Stem Cells -- Therapeutic use -- Periodicals; Stem Cells -- Transplantation -- Periodicals; 616.0277405
• DOI: 10.1155/2020/8868849
• Languages: English
• ISSNs: 1687-966X

Abstract

Abstract : The precise mechanism about drug resistance of cancer stem cells (CSCs) has not yet been completely understood. Based on the expression of CD44 and CD133, two well-recognized cell surface markers for CSC identification, we tried to separate HCT8 colorectal cancer cells into different subpopulations and then investigated how the expression of CD44 and CD133 associated with doxorubicin (DXR) resistance. Interestingly, DXR resistance was observed in CD44 + CD133 + (P < 0.01 vs. all other subpopulations), but not in CD44 + CD133 - cells. CD44 + CD133 + cells also showed an enhanced expression of ABCB1 and drug efflux ability (P < 0.001 vs. all other subpopulations), but verapamil, an inhibitor of ABCB1, only partially mitigated the DXR resistance. Independent on the accumulation of DXR, lower level of reactive oxygen species and higher expression of Nrf2 were detected in CD44 + CD133 + than CD44 + CD133 - cells (P < 0.05 ). Unexpectedly, silencing CD133 by siRNA only partially enhanced the cytotoxicity of DXR, but did not obviously change the expression of ABCB1 and the accumulation of DXR in CD44 + CD133 + cells. Complex mechanisms, including drug excretion and redox regulation, are likely involved in the DXR resistance of CD133-positive cells, suggesting the difficulty of drug resistance problem in cancer chemotherapy.